Literature DB >> 2477345

Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.

D H Shevrin1, T E Lad, L J Kilton, M A Cobleigh, R R Blough, L L Weidner, N J Vogelzang.   

Abstract

Fludarabine Phosphate (FP), the 2-fluoro, 5'phosphate derivative of adenosine arabinoside (ara-A), was studied in 18 patients with advanced renal cell carcinoma. These patients had measurable disease and had not received chemotherapy. FP was administered at a loading dose of 20 mg/m2 followed by a 48-hour infusion at 30 mg/m2/day given every 21 days. There were no complete or partial responses seen. Toxicity was mainly hematologic, with leukopenia most commonly observed. FP given in this manner had no activity in advanced renal cell carcinoma.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2477345     DOI： 10.1007/bf00170869

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  4 in total

1.  Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.

Authors:  L Balducci; B Blumenstein; D D Von Hoff; M Davis; H E Hynes; R M Bukowski; E D Crawford
Journal:  Cancer Treat Rep       Date:  1987-05

2.  Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells.

Authors:  W Plunkett; S Chubb; L Alexander; J A Montgomery
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

3.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

4.  Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.

Authors:  J J Hutton; D D Von Hoff; J Kuhn; J Phillips; M Hersh; G Clark
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701
  4 in total
  3 in total

Review 1.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 2.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  Combined Effects of Fludarabine and Interferon Alpha on Autophagy Regulation Define the Phase of Cell Survival and Promotes Responses in LLC-MK2 and K562 Cells.

Authors:  Pathompong Bowornruangrit; Supeecha Kumkate; Wipawan Sirigulpanit; Vijittra Leardkamolkarn
Journal:  Med Sci (Basel)       Date:  2022-03-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.